



**Australian Government**

**Department of Health**

**COMMUNICABLE  
DISEASES  
INTELLIGENCE**

2018      Volume 42  
PII:S2209-6051(18)00021-0

**Australian Group on Antimicrobial-resistance (AGAR)  
Australian Staphylococcus aureus Sepsis Outcome  
Programme (ASSOP) Annual Report 2016**

Geoffrey W Coombs; Denise A Daley; Yung Thin Lee and Stanley Pang  
on behalf of the Australian Group on Antimicrobial-resistance

# COMMUNICABLE DISEASES INTELLIGENCE

© Commonwealth of Australia 2018

**ISSN: 2209-6051 Online**

This work is copyright. You may download, display, print and reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as permitted by the Copyright Act 1968 or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given the specific written permission from the Commonwealth to do so. Requests and inquiries concerning reproduction and rights are to be sent to the Online, Services and External Relations Branch, Department of Health, GPO Box 9848, Canberra ACT 2601, or by email to [copyright@health.gov.au](mailto:copyright@health.gov.au).

Communicable Diseases Intelligence aims to disseminate information on the epidemiology and control of communicable diseases in Australia. Communicable Diseases Intelligence invites contributions dealing with any aspect of communicable disease epidemiology, surveillance or prevention and control in Australia. Submissions can be in the form of original articles, short reports, surveillance summaries, reviews or correspondence. Instructions for authors can be found in *Commun Dis Intell* 2016;40(1):E189–E193.

Communicable Diseases Intelligence contributes to the work of the Communicable Diseases Network Australia.

<http://www.health.gov.au/cdna>

## **Editor**

Cindy Toms

## **Deputy Editor**

Phil Wright

## **Editorial and Production Staff**

Leroy Trapani, Kasra Yousefi

## **Editorial Advisory Board**

Peter McIntyre (Chair), David Durrheim, Mark Ferson, John Kaldor, Martyn Kirk

## **Website**

<http://www.health.gov.au/cdi>

## **Contacts**

Communicable Diseases Intelligence is produced by:  
Health Protection Policy Branch  
Office of Health Protection  
Australian Government Department of Health  
GPO Box 9848, (MDP 6) CANBERRA ACT 2601

**Email:** [cdi.editor@health.gov.au](mailto:cdi.editor@health.gov.au)

This journal is indexed by Index Medicus and Medline.

## **Disclaimer**

Opinions expressed in Communicable Diseases Intelligence are those of the authors and not necessarily those of the Australian Government Department of Health or the Communicable Diseases Network Australia. Data may be subject to revision.

## **Submit an Article**

You are invited to submit your next communicable disease related article to the Communicable Diseases Intelligence (CDI) for consideration. More information regarding CDI can be found at: <http://health.gov.au/cdi>. Further enquiries should be directed to: [cdi.editor@health.gov.au](mailto:cdi.editor@health.gov.au).

# Australian Group on Antimicrobial-resistance (AGAR) Australian *Staphylococcus aureus* Sepsis Outcome Programme (ASSOP) Annual Report 2016

Geoffrey W Coombs; Denise A Daley; Yung Thin Lee and Stanley Pang on behalf of the Australian Group on Antimicrobial-resistance

## Abstract

From 1<sup>st</sup> January to 31<sup>st</sup> December 2016, 32 institutions around Australia participated in the Australian *Staphylococcus aureus* Sepsis Outcome Programme (ASSOP). The aim of ASSOP 2016 was to determine the proportion of *Staphylococcus aureus* bacteraemia (SAB) isolates in Australia that are antimicrobial resistant, with particular emphasis on susceptibility to methicillin and to characterise the molecular epidemiology of the methicillin-resistant isolates. A total of 2,540 *S. aureus* bacteraemia episodes were reported, of which 19.7% were methicillin-resistant. The 30-day all-cause mortality associated with methicillin-resistant SAB was 23.1% which was significantly higher than the 15.3% mortality associated with methicillin-susceptible SAB. With the exception of the  $\beta$ -lactams and erythromycin, antimicrobial-resistance in methicillin-susceptible *S. aureus* (MSSA) was rare. However, in addition to the  $\beta$ -lactams approximately 45% of methicillin-resistant *S. aureus* (MRSA) were resistant to erythromycin and ciprofloxacin and approximately 14% resistant to co-trimoxazole, tetracycline and gentamicin. When applying the EUCAST breakpoints, teicoplanin resistance was detected in two *S. aureus* isolates. Resistance was not detected for vancomycin and linezolid. Resistance to non-beta-lactam antimicrobials was largely attributable to 2 healthcare associated MRSA clones; ST22-IV [2B] (EMRSA-15) and ST239-III [3A] (Aus-2/3 EMRSA). ST22-IV [2B] (EMRSA-15) is the predominant healthcare associated clone in Australia. Seventy two percent of methicillin-resistant SAB were due to community associated clones. Although polyclonal almost 60% of community associated clones were characterised as ST93-IV [2B] (Queensland CA-MRSA), ST5-IV [2B] and ST1-IV [2B]. CA-MRSA in particular the ST45-V<sub>T</sub> [5C2&5] clone has acquired multiple antimicrobial-resistance determinants including ciprofloxacin, erythromycin, clindamycin, gentamicin and tetracycline. Twelve percent of CA-MRSA were ST45-V<sub>T</sub> [5C2&5]. As CA-MRSA is well established in the Australian community it is important antimicrobial-resistance patterns in community- and healthcare-associated SAB is monitored as this information will guide therapeutic practices in treating *S. aureus* sepsis.

**Keywords:** Australian Group on Antimicrobial-resistance (AGAR); antimicrobial-resistance surveillance; *Staphylococcus aureus*, methicillin-susceptible *Staphylococcus aureus* (MSSA), methicillin-resistant *Staphylococcus aureus* (MRSA), bacteraemia

## Background

Globally, *Staphylococcus aureus* is one of the most frequent causes of hospital-acquired and

community-acquired blood stream infections.<sup>1</sup> Although there are a wide variety of manifestations of serious invasive infection caused by *S. aureus*, in the great majority of these cases

the organism can be detected in blood cultures. Therefore, *S. aureus* bacteraemia (SAB) is considered a very useful marker for serious invasive infection.<sup>2</sup>

Although prolonged antimicrobial therapy and prompt source control are used to treat SAB,<sup>3</sup> mortality ranges from as low as 2.5% to as high as 40%.<sup>4-6</sup> Mortality rates however, are known to vary significantly with patient age, clinical manifestation, co-morbidities and methicillin resistance.<sup>7,8</sup> A prospective study of SAB conducted in 27 laboratories in Australia and New Zealand found a 30-day all-cause mortality of 20.6%.<sup>9</sup> On univariate analysis increased mortality was significantly associated with older age, European ethnicity, methicillin resistance, infections not originating from a medical device, sepsis syndrome, pneumonia/empyema and treatment with a glycopeptide or other non- $\beta$ -lactam antibiotic.

The Australian Group on Antimicrobial-resistance (AGAR), a network of laboratories located across Australia, commenced surveillance of antimicrobial-resistance in *S. aureus* in 1986.<sup>10</sup> In 2013, AGAR commenced the Australian Staphylococcal Sepsis Outcome Programme (ASSOP).<sup>11</sup> The primary objective of ASSOP 2016 was to determine the proportion of SAB isolates demonstrating antimicrobial-resistance with particular emphasis on:

- assessing susceptibility to methicillin
- molecular epidemiology of methicillin-resistant *S. aureus* (MRSA).

## Methodology

### Participants

Thirty-two laboratories from all 8 Australian states and territories.

### Collection Period

From 1<sup>st</sup> January to 31<sup>st</sup> December 2016, the 32 laboratories collected all *S. aureus* isolated from

blood cultures. *S. aureus* with the same antimicrobial susceptibility profiles isolated from a patient's blood culture within 14 days of the first positive culture were excluded. A new *S. aureus* sepsis episode in the same patient was recorded if it was identified by a culture of blood collected more than 14 days after the last positive culture. Data were collected on age, sex, date of admission and discharge (if admitted), and mortality at 30 days from date of first positive blood culture. To avoid interpretive bias, no attempt was made to assign attributable mortality. Each episode of bacteraemia was designated healthcare onset if the first positive blood culture(s) in an episode were collected >48 hours after admission.

### Laboratory Testing

Participating laboratories performed antimicrobial susceptibility testing using the Vitek2<sup>®</sup> (bioMérieux, France) or the Phoenix<sup>™</sup> (BD, USA) automated microbiology systems according to the manufacturer's instructions. *S. aureus* was identified by morphology and positive results of at least one of the following tests: Vitek MS<sup>®</sup> (bioMérieux, France), matrix-assisted laser desorption ionization (MALDI) biotyper (Bruker Daltonics, Germany), slide coagulase, tube coagulase, appropriate growth on chromogenic agar and demonstration of deoxyribonuclease production. Additional tests, such as fermentation of mannitol, growth on mannitol-salt agar or polymerase chain reaction (PCR) for the presence of the *nuc* gene, may have been performed for confirmation.

Minimum inhibitory concentration (MIC) data and isolates were referred to the AMRID Research Laboratory at the School of Veterinary and Life Sciences, Murdoch University. Clinical and Laboratory Standards Institute (CLSI)<sup>12</sup> and European Committee on Antimicrobial Susceptibility Testing (EUCAST)<sup>13</sup> breakpoints were utilised for interpretation. Isolates with a resistant or an intermediate category were classified as non-susceptible. Linezolid and daptomycin non-susceptible isolates were retested by Etest<sup>®</sup> (bioMérieux) using the Mueller-Hinton agar recommended by the manufacturer.

*S. aureus* ATCC 29213 was used as the control strain. High level mupirocin-resistance was determined using a mupirocin 200 µg disk according to CLSI guidelines on all isolates with a mupirocin MIC >8 mg/L by Vitek2<sup>®</sup> or >256 mg/L by Phoenix<sup>™</sup>.<sup>12</sup> Multi-resistance was defined as resistance to 3 or more of the following non-β-lactam antimicrobials: vancomycin, teicoplanin, erythromycin/clindamycin, tetracycline, ciprofloxacin, gentamicin, cotrimoxazole, fusidic acid, rifampicin, high level mupirocin, and linezolid.

Molecular testing was performed by whole genome sequencing using the MiSeq platform (Illumina, San Diego, USA). Sequencing results were analysed using the Nullarbor pipeline.<sup>14</sup> *spa* types were determined using the online *spa* typing tool described by Bartels *et al.*<sup>15</sup> SCCmec elements were identified using SCCmec sequences described by Monecke *et al.*<sup>16</sup>

Chi-square tests for comparison of 2 proportions and calculation of 95% confidence intervals (95%CI) were performed using MedCalc for Windows, version 12.7 (MedCalc Software, Ostend Belgium).

Approval to conduct the prospective data collection was given by the research ethics committee associated with each participating laboratory.

## Results

From 1<sup>st</sup> January to the 31<sup>st</sup> December 2016, 2,540 unique episodes of *S. aureus* bacteraemia were identified. A significant difference ( $p < 0.0001$ ) was seen in patient sex with 65.4% (1,661) being male (95% CI 63.5 – 67.3). The average age of patients was 58 years ranging from 0 – 102 years with a median age of 62 years. Overall 76.2% (1,936/2,540) of episodes were community onset (95% CI 74.5% – 77.9%). All-cause mortality at 30-days was 16.7% (95% CI 15.3 – 18.2). Methicillin-resistant SAB mortality was 23.1% (95% CI 19.5 – 27.0) which was significantly higher than for methicillin-susceptible SAB mortality (15.3%, 95% CI 13.8 – 16.9) ( $p = 0.0003$ ).

## Methicillin-Susceptible *Staphylococcus aureus* (MSSA) Antimicrobial Susceptibility

Overall 80.3% (2,040) of the 2,540 isolates were methicillin-susceptible of which 77.2% (1,571) were penicillin-resistant (MIC >0.12 mg/L). However, as β-lactamase was detected in 66 phenotypically penicillin susceptible isolates, 80.4% of MSSA were considered penicillin-resistant. Apart from erythromycin non-susceptibility, resistance to the non-β-lactam antimicrobials amongst MSSA was rare, ranging from 0.1% to 3.2% (Table 1). There were 7 isolates reported by Vitek2<sup>®</sup> as non-susceptible to daptomycin (MIC >1.0mg/L). By Etest<sup>®</sup> three of the isolates were considered susceptible (MICs 0.25, 0.38 and 0.5mg/L). Four isolates had Etest<sup>®</sup> MICs of 1.5, 2.0 (2 isolates) and 3.0 mg/L and therefore were considered non-susceptible. By Vitek2<sup>®</sup> two isolates were linezolid-resistant (MIC >4 mg/L). However by Etest<sup>®</sup> the isolates had an MIC ≤4 mg/L (0.5 and 1.5 mg/L) and were therefore considered linezolid-susceptible. All MSSA were vancomycin and teicoplanin and susceptible. Twenty four (1.2%) of 2,036 isolates had high level mupirocin-resistance of which 15 isolates were referred from Queensland. Inducible resistance to clindamycin was determined by the Vitek2<sup>®</sup> susceptibility system. Of the 1,798 isolates tested, 10.1% (181) were erythromycin non-susceptible/clindamycin intermediate/susceptible (CLSI breakpoints) of which 87.9% (159) were classified as having inducible clindamycin resistance. Multi-resistance was uncommon in MSSA (0.7%, 14/1,922).

There were no significant differences in interpretation for any drug when CLSI or EUCAST non susceptibility breakpoints were utilised ( $P > 0.05$ ).

## MRSA Antimicrobial Susceptibility

The proportion of *S. aureus* that were MRSA was 19.7% (95%CI 18.2 – 21.3). The 500 MRSA identified were either cefoxitin screen positive by Vitek2<sup>®</sup> (417) or had a cefoxitin MIC >4 by Phoenix<sup>™</sup> (83). All 500 MRSA isolates were

**Table 1: The number and proportion of methicillin-susceptible *Staphylococcus aureus* (MSSA) isolates non-susceptible to penicillin and the non-β-lactam antimicrobials, Australia, 2016**

Antimicrobial	Tested	Breakpoint (mg/L)	Non-Susceptible	
			n	%
Penicillin	2,035	>0.12*	1,571	77.2
Vancomycin	2,035	>2*	0	0.0
Teicoplanin	2,037	>8 <sup>†</sup>	0	0.0
		>2 <sup>‡</sup>	0	0.0
Rifampicin	1,981	>1 <sup>†</sup>	3	0.2
		>0.5 <sup>‡</sup>	3	0.2
Fusidic Acid	2,036	>1 <sup>†</sup>	65	3.2
Gentamicin	2,038	>4 <sup>†</sup>	9	0.4
		>1 <sup>†</sup>	16	0.8
Erythromycin	2,036	>0.5 <sup>†</sup>	225	11.1
		>2 <sup>‡</sup>	190	9.3
Clindamycin	2,035	>0.5*	20	1.0
Tetracycline	1,814	>4 <sup>†</sup>	40	2.2
		>2 <sup>‡</sup>	40	2.2
Co-trimoxazole	2,038	>2/38 <sup>†</sup>	50	2.5
		>4/76 <sup>‡</sup>	46	2.3
Ciprofloxacin	2,036	>1*	59	2.9
Nitrofurantoin	1,930	>32 <sup>†</sup>	7	0.4
		>64 <sup>‡</sup>	1	0.1
Daptomycin	2,037	>1*	4	0.2
Linezolid	2,038	>4*	0	0

\*CLSI and EUCAST non-susceptible breakpoint

<sup>†</sup>CLSI non-susceptible breakpoint

<sup>‡</sup>EUCAST non-susceptible breakpoint

phenotypically penicillin-resistant. Amongst the MRSA isolates, non-susceptibility to non-β-lactam antimicrobials was common except for rifampicin, fusidic acid and nitrofurantoin where resistance was below 3.2% (Table 2). There were 4 isolates reported by Vitek2<sup>®</sup> as non-susceptible to daptomycin (MIC >1.0mg/L). By Etest<sup>®</sup> the isolates had MICs of 1.5 (2 isolates) and 2 mg/L (2 isolates). When using the EUCAST resistant breakpoint of >2 mg/L one isolate was teicoplanin resistant (MIC = 4 mg/L). However, using the CLSI resistant breakpoint of >8 mg/L the isolate was classified as susceptible. One MRSA had a vancomycin MIC of 4.0mg/L by both Vitek2<sup>®</sup> and Etest<sup>®</sup> however no *van* genes were present. Four (0.8%) of 498 MRSA isolates tested had high level mupirocin-resistance. Inducible resistance to clindamycin was determined by the Vitek2<sup>®</sup> susceptibility

system. Of the 417 isolates tested by Vitek2<sup>®</sup>, 31.2% (130) were erythromycin non-susceptible/clindamycin intermediate/susceptible (CLSI and EUCAST breakpoints) of which 83.9% (109) were classified as having inducible clindamycin resistance. Multi-resistance was seen in 11.8% of MRSA. This was a significant decrease from the 2015 study (24.3%, p<0.0001).

There were no significant differences in interpretation for any drug when CLSI or EUCAST non susceptibility breakpoints were utilised (P>0.05).

### MRSA Molecular Epidemiology

Whole genome sequencing was performed on 93.6% (468/500) of the MRSA. Based on molecular typing, 27.6% (129) and 72.4% (339) of isolates

**Table 2: The number and proportion of methicillin-resistant *Staphylococcus aureus* (MRSA) isolates non-susceptible to penicillin and the non- $\beta$ -lactam antimicrobials, Australia, 2016**

Antimicrobial	Tested	Breakpoint (mg/L)	Non-Susceptible (%)	
			n	%
Penicillin	500	>0.12*	500	100
Vancomycin	500	>2*	1	0.2
Teicoplanin	500	>8 <sup>†</sup>	0	0
		>2 <sup>‡</sup>	1	0.2
Rifampicin	498	>1 <sup>†</sup>	13	2.6
		>0.5 <sup>†</sup>	13	2.6
Fusidic Acid	500	>1 <sup>†</sup>	16	3.2
Gentamicin	500	>4 <sup>†</sup>	70	14.0
		>1 <sup>†</sup>	76	15.2
Erythromycin	500	>0.5 <sup>†</sup>	219	43.8
		>2 <sup>‡</sup>	209	41.8
Clindamycin	500	>0.5 <sup>†</sup>	69	13.8
Tetracycline	417	>4 <sup>†</sup>	63	15.1
		>2 <sup>‡</sup>	63	15.1
Co-trimoxazole	500	>2/38 <sup>†</sup>	56	11.2
		>4/76 <sup>‡</sup>	54	10.8
Ciprofloxacin	500	>1*	217	43.5
Nitrofurantoin	488	>32 <sup>†</sup>	1	0.2
		>64 <sup>‡</sup>	0	0
Daptomycin	500	>1*	4	0.8
Linezolid	500	>4*	0	0

\*CLSI and EUCAST non-susceptible breakpoint

<sup>†</sup>CLSI non-susceptible breakpoint

<sup>‡</sup>EUCAST non-susceptible breakpoint

were classified as healthcare-associated MRSA (HA-MRSA) and community-associated MRSA (CA-MRSA) clones respectively (Table 3).

### Healthcare-associated methicillin-resistant *Staphylococcus aureus*

For the 129 HA-MRSA isolates, 42.6% (55) were epidemiologically classified as hospital onset and 57.4% (74) were classified as community onset. Five HA-MRSA clones were identified: 97 isolates of ST22-IV [2B] (EMRSA-15) (20.7% of MRSA typed and 3.9% of *S. aureus*); 29 isolates of ST239-III [3A] (Aus-2/3 EMRSA) (6.2% and 1.2%) and single isolates of ST5-II [2A] (USA100/New York Japan), ST8-II [2B] (Irish-1) and ST8-III [2B] (EMRSA-17).

ST22-IV [2B] (EMRSA-15) was the dominant HA-MRSA clone in Australia accounting for 75% of HA-MRSA ranging from 0% in the Northern Territory to 100% in Tasmania (Table 4). ST22-IV [2B] (EMRSA-15) was PVL negative and using CLSI breakpoints 98.0% and 47.5% were ciprofloxacin and erythromycin non-susceptible respectively.

ST239-III [3A] (Aus-2/3 EMRSA) accounted for 22.5% of HA-MRSA ranging from 0% in Tasmania to 100% in the Northern Territory (Table 4). PVL negative ST239-III [3A] (Aus-2/3 EMRSA) were typically resistant to erythromycin (96.6%), co-trimoxazole (82.8%), ciprofloxacin (96.6%), gentamicin (93.1%), tetracycline (88.0%) and clindamycin (69.0%).

**Table 3: Proportion of healthcare-associated and community-associated methicillin-resistant *Staphylococcus aureus*, Australia, 2016 by clone, healthcare and community onset, and Panton-Valentine leucocidin carriage**

Strain	Total		Onset				PVL Positive	
			Healthcare		Community		n	% <sup>†</sup>
	n	% <sup>*</sup>	n	% <sup>†</sup>	n	% <sup>†</sup>	n	% <sup>†</sup>
<b>Healthcare Associated MRSA</b>								
ST22-IV [2B] (EMRSA-15)	97	20.7	40	41.2	57	58.8	0	0
ST239-III [3A] (Aus-2/3)	29	6.2	13	44.8	16	55.2	0	0
ST5-II (NY/Japan/USA100 variant)	1	0.2	1	100	0	0	0	0
ST8-II (Irish-1)	1	0.2	0	0	1	100	0	0
ST8-III (EMRSA 17)	1	0.2	1	100	0	0	0	0
Total HA-MRSA	129	27.6	55	42.6	74	57.4	0	0
<b>Community Associated MRSA</b>								
ST93-IV [2B] (Queensland)	101	21.6	12	11.9	89	88.1	97	96.0
ST5-IV	50	10.7	10	20.0	40	80.0	13	26.0
ST1-IV	45	9.6	12	26.7	33	73.3	3	6.7
ST45-Vt	41	8.8	10	24.4	31	75.6		0
ST30-IV	19	4.1	6	31.6	13	68.4	12	63.2
ST78-IV	17	3.6	3	17.6	14	82.4		0
ST97-IV	7	1.5	1	14.3	6	85.7		0
ST188-IV	4	0.9	2	50.0	2	50.0		0
ST72-IV	4	0.9	1	25.0	3	75.0		0
ST1-I	3	0.6		0	3	100		0
ST59-IV	3	0.6		0	3	100		0
ST59-Vt	3	0.6		0	3	100	2	66.7
ST5-Vt	3	0.6	1	33.3	2	66.7		0
ST872-IV	3	0.6		0	3	100		0
ST8-IV	3	0.6	1	33.3	2	66.7	3	100
ST953-IV	3	0.6	3	100		0		0
ST1-Vt	2	0.4	1	50.0	1	50.0		0
ST45-IV	2	0.4		0	2	100		0
ST73-IV	2	0.4	1	50.0	1	50.0		0
ST772-Vt	2	0.4	1	50.0	1	50.0	1	50.0
ST834-IV	2	0.4	1	50.0	1	50.0		0
ST835-IV	2	0.4		0	2	100		0
ST1232-Vt	1	0.2		0	1	100	1	100
ST1420-IV	1	0.2		0	1	100	1	100
ST149-IV	1	0.2		0	1	100		0
ST1850-IV	1	0.2	1	100		0	1	100
ST1slv-IV	1	0.2		0	1	100		0
ST30-V	1	0.2		0	1	100	1	100
ST30-Vt	1	0.2		0	1	100	1	100
ST338-Vt	1	0.2		0	1	100	1	100
ST45-V	1	0.2	1	100		0		0
ST5slv-IV	1	0.2		0	1	100		0
ST5-V	1	0.2		0	1	100		0
ST5-VI	1	0.2		0	1	100		0
ST672-Vt	1	0.2	1	100		0		0
ST6-IV	1	0.2	1	100		0		0
ST6slv-Vt	1	0.2		0	1	100		0
ST762-IV	1	0.2		0	1	100		0
ST88-IV	1	0.2		0	1	100		0
ST8-Vt	1	0.2		0	1	100		0
<b>Total CA-MRSA</b>	<b>339</b>	<b>72.4</b>	<b>70</b>	<b>20.6</b>	<b>269</b>	<b>79.4</b>	<b>137</b>	<b>40.4</b>
<b>Grand Total</b>	<b>468</b>	<b>100</b>	<b>125</b>	<b>26.7</b>	<b>343</b>	<b>73.3</b>	<b>137</b>	<b>40.4</b>

\*Percentage of all MRSA typed

†Percentage of the strain

**Table 4: The number and proportion of healthcare associated methicillin-resistant *Staphylococcus aureus* (MRSA) multilocus sequence types, Australia, 2016, by region**

Type	ACT		NSW		NT		Qld		SA		Tas		Vic		WA		Aus	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
ST22-IV	4	66.7	34	68.0	3	60.0	22	81.5	8	100	16	80.0	10	90.9	97	75.2		
ST239-III	2	33.3	14	28.0	2	100	5	18.5			3	15.0	1	9.1	29	22.5		
ST5-II											1	5.0			1	0.8		
ST8-II			1	2.0											1	0.8		
ST8-III			1	2.0											1	0.8		
Total	6	100	50	100	2	100	27	100	8	100	20	100	11	100	129	100		

ACT = Australian Capital Territory; NSW = New South Wales; NT = Northern Territory; Qld = Queensland; SA = South Australia; Tas = Tasmania; Vic = Victoria; WA = Western Australia; Aus = Australia

**Table 5: The number and proportion of the major community associated methicillin-resistant *Staphylococcus aureus* (MRSA) multilocus sequence types, Australia (>10 isolates), 2016, by region**

Type	ACT		NSW		NT		Qld		SA		Tas		Vic		WA		Aus	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
ST93-IV			16	17.8	26	66.7	19	32.8	8	23.5	1	33.3	10	25.3	21	31.8	101	29.8
ST5-IV			11	12.2	8	20.5	14	24.1	4	11.8			6	14.0	7	10.6	50	14.7
ST1-IV	1	16.7	11	12.2	3	7.7	5	8.6	11	32.4	2	66.7	3	7.0	9	13.6	45	13.3
ST45-Vt	1	16.7	29	32.2					4	11.8			7	16.3			41	12.1
ST30-IV			9	10			4	6.9					6	14.0			19	5.6
ST78-IV	1	16.7							3	8.8					13	19.7	17	5.0
Other	3	50	14	15.6	2	5.1	16	27.6	4	11.8			11	25.6	17	24.2	66	19.5
Total	6	100	90	100	39	100	58	100	34	100	3	100	43	100	66	100	339	100

ACT = Australian Capital Territory; NSW = New South Wales; NT = Northern Territory; Qld = Queensland; SA = South Australia; Tas = Tasmania; Vic = Victoria; WA = Western Australia; Aus = Australia

## Community-associated methicillin-resistant *Staphylococcus aureus*

For the 339 CA-MRSA isolates, 20.6% (70) of episodes were epidemiologically classified as hospital-onset and 79.4% (269) classified as community-onset. Based on the multi locus sequence type and the *SCCmec* type 40 CA-MRSA clones were identified (Table 3). Overall 80.5% of CA-MRSA were classified into six clones each having more than ten isolates: ST93-IV [2B] (Queensland CA-MRSA) (21.6% of MRSA typed and 4.2% of *S. aureus*); ST5-IV (10.7% and 2.1%); ST1-IV (9.6% and 1.9%); ST45-VT (8.8% and 1.7%); ST30-IV (4.1% and 0.8%); and ST78-IV (3.6% and 0.7%).

ST93-IV [2B] (Queensland CA-MRSA) accounted for 29.8% of CA-MRSA ranging from 0% in the Australian Capital Territory to 66.7% in the Northern Territory (Table 5). Typically PVL positive, 78.2% (79/101) of ST93-IV [2B] (Queensland CA-MRSA) were resistant to the  $\beta$ -lactams only or additionally resistant to erythromycin (14.9%, 15/101) or erythromycin and clindamycin (6.9%, 7/101).

ST5-IV accounted for 14.7% of CA-MRSA and was isolated in all regions of Australia except the Australian Capital Territory and Tasmania ranging from 0% to 24.1% in Queensland (Table 5). ST5-IV, 26% PVL positive, was typically resistant to the  $\beta$ -lactams only 40% (20/50)  $\beta$ -lactams and co-trimoxazole (26%, 13/50), or additionally resistant to erythromycin (10%, 5/50), fusidic acid (5.7%, 5/50), ciprofloxacin and erythromycin (6.0% 3/50), and one (2.0%) each of clindamycin and erythromycin, erythromycin and fusidic acid, erythromycin and tetracycline or erythromycin, clindamycin and tetracycline.

ST1-IV accounted for 13.3% of CA-MRSA ranging from 7.7% in the Northern Territory to 35.3% in South Australia (Table 5). Typically PVL negative, 64.4% of isolates were resistant to the  $\beta$ -lactams only (29/45) or additionally resistant to erythromycin (11.1%, 5/45), fusidic acid (4.4%, 2/45), erythromycin and fusidic acid (4.4%, 2/45) erythromycin, clindamycin and

tetracycline (4.4%, 2/45) and one (2.2%) each of ciprofloxacin, ciprofloxacin and erythromycin, ciprofloxacin and gentamicin, erythromycin and tetracycline, and erythromycin, clindamycin, fusidic acid and tetracycline.

ST45-VT accounted for 12.1% of CA-MRSA and was isolated primarily in New South Wales (Table 5). All isolates were PVL negative and were resistant to the  $\beta$ -lactams. Isolates were additionally non-susceptible to erythromycin, ciprofloxacin, gentamicin and tetracycline (29.3%, 12/41), ciprofloxacin (19.5%, 8/41) erythromycin, ciprofloxacin and tetracycline (14.6%, 6/41), erythromycin, ciprofloxacin, clindamycin, gentamicin and tetracycline (9.8%, 4/41), erythromycin, ciprofloxacin and gentamicin (7.3%, 3/41) two (4.9%) of erythromycin, ciprofloxacin and clindamycin, and ciprofloxacin, gentamicin and tetracycline, and one (2.4%) each of co-trimoxazole, erythromycin and ciprofloxacin, ciprofloxacin and gentamicin, ciprofloxacin and tetracycline.

ST30-IV accounted for 5.6% of CA-MRSA and was isolated only in New South Wales, Victoria and Queensland (Table 5). Typically PVL positive 89.5% of isolates were resistant to the  $\beta$ -lactams only (17/19). One isolate (5.3%) was resistant to clindamycin and erythromycin and one isolate to clindamycin and co-trimoxazole.

ST78-IV accounted for 5.0% of CA-MRSA and was predominantly in Western Australia (Table 5). Isolates were resistant to the  $\beta$ -lactams and erythromycin (100%, 17/17).

Overall 92.3% of CA-MRSA were non-multiresistant including 49.3% resistant to the  $\beta$ -lactams only. However 26 (7.7%) CA-MRSA isolates were multiresistant.

### Panton-Valentine leucocidin

Overall 137 (29.3%) MRSA were PVL positive, including 40.4% of CA-MRSA (Table 3).

## Discussion

The AGAR surveillance programmes collect data on antimicrobial-resistance, focussing on bloodstream infections caused by *S. aureus*, *Enterococcus* and *Enterobacteriaceae*. All data being collected in the AGAR programs are generated as part of routine patient care in Australia with most being available through laboratory and hospital bed management information systems. Isolates are referred to a central laboratory where strain and antimicrobial-resistance determinant characterisation is performed. As the programmes are similar to those conducted in Europe comparison of Australia antimicrobial-resistance data with other countries is possible. ([http://www.ecdc.europa.eu/en/healthtopics/antimicrobial\\_resistance/database/Pages/database.aspx](http://www.ecdc.europa.eu/en/healthtopics/antimicrobial_resistance/database/Pages/database.aspx)).

In the 2016 European Centre for Disease Prevention and Control and Prevention (ECDC) SAB surveillance program, the European Union/European Economic Area (EU/EEA) population-weighted mean percentage of *S. aureus* resistant to methicillin was 13.7% (95% CI 13 - 14), ranging from 1.2% (95% CI 1 - 2) in the Netherlands and Norway to 50.5% (95% CI 51 - 63) in Romania. (<http://ecdc.europa.eu/en/publications/Publications/antimicrobial-resistance-europe-2016.pdf>)

In ASSOP 2016, 19.7% (95% CI 18.2 - 21.3) of the 2,540 SAB episodes were methicillin-resistant.

This compares to 19.1% (95% CI 17.5 - 21.0) in ASSOP 2013<sup>11</sup>, 18.8% (95%CI 17.2 - 20.5) in ASSOP 2014<sup>17</sup> and 18.2% (95% CI 16.7- 19.8) in ASSOP 2015.<sup>31</sup> However, for 20 of the 30 European countries (primarily the northern European countries, Germany, France and the United Kingdom) the percentage of SAB isolates resistant to methicillin was less than that reported in ASSOP 2016. Similar to Europe, which has seen the EU/EEA population-weighted mean percentage decrease significantly from 23.2% in 2009 to 13.7% in 2016, the percentage of methicillin-resistant SAB in Australia has decreased from 23.8% (95% CI

21.4 - 26.4) in 2007 to 19.1% (95%CI 17.5 -21.0) in 2016 (P<0.0001). The decrease in methicillin-resistant SAB is consistent with what has been reported elsewhere<sup>19,20</sup> and is believed to be attributed to the implementation of antimicrobial stewardship and a package of improved infection control procedures including hand hygiene, MRSA screening and decolonisation, patient isolation and infection prevention care bundles.<sup>21-25</sup> However, unlike Europe, Australia has a high prevalence of CA-MRSA and so further reduction in the proportion of SAB due to MRSA may prove problematic.

In ASSOP 2016, the all-cause mortality at 30-days was 16.7% (95% CI 15.3 - 18.2). In comparison, the 2008 Australian New Zealand Cooperative on Outcomes in Staphylococcal Sepsis (ANZCOSS) reported a significantly higher figure of 20.6% (95% CI 18.8 - 22.5, P<0.0001), and when adjusted for Australian institutions only was 25.9% (personal communication). MRSA-associated SAB mortality remains high (23.1%, 95% CI 19.5 - 27.0) and was significantly higher than MSSA-associated SAB mortality (15.3%, 95% CI 13.8 - 16.9) p=0.0003. Although it has recently been shown that invasive MRSA infection may be more life-threatening, partially because of the inferior efficacy of the standard treatment, vancomycin,<sup>9</sup> the emergence of hyper-virulent CA-MRSA clones such as ST93-IV [2B] (Queensland CA-MRSA), causing healthcare-associated SAB is of concern.<sup>26</sup>

With the exception of the  $\beta$ -lactams and erythromycin, antimicrobial-resistance in MSSA remains rare. However, in addition to the  $\beta$ -lactams approximately 50% of MRSA were resistant to erythromycin and ciprofloxacin and approximately 15% resistant to co-trimoxazole, tetracycline and gentamicin. Resistance was largely attributable to 2 healthcare associated MRSA clones, ST22-IV [2B] (EMRSA-15), which is typically ciprofloxacin and erythromycin resistant, and ST239-III [3A] (Aus-2/3 EMRSA) which is typically erythromycin, clindamycin, ciprofloxacin, co-trimoxazole, tetracycline and gentamicin-resistant. From the early 1980s until recently, the multi-resistant ST239-III [3A]

(Aus-2/3 EMRSA) was the dominant HA-MRSA clone in Australian hospitals. However, ST22-IV [2B] (EMRSA-15) has replaced ST239-III [3A] (Aus-2/3 EMRSA) as the most prevalent HA-MRSA isolated from clinical specimens and this change has occurred throughout most of the country.<sup>27</sup> In ASSOP 2016, approximately 21% of MRSA were characterised as ST22-IV [2B] (EMRSA-15). CA-MRSA, in particular the ST45-V<sub>T</sub> clone (8.8% of MRSA), has acquired multiple antimicrobial-resistance determinants including ciprofloxacin, erythromycin, clindamycin, gentamicin and tetracycline.

Resistance was not detected for vancomycin, linezolid or teicoplanin when CLSI interpretive criteria were applied. However, one isolate was teicoplanin non-susceptible when EUCAST criteria were applied.

Approximately 20.6% of SAB caused by CA-MRSA were healthcare-onset. Although, in several parts of the United States the CA-MRSA clone USA300 has replaced the HA-MRSA clone ST5-II [2A] (USA100) as a cause of healthcare associated MRSA infection,<sup>28</sup> transmission of CA-MRSA in Australian hospitals is thought to be rare.<sup>29,30</sup> Consequently, it is likely that many of the healthcare onset CA-MRSA SAB infections reported in ASSOP 2016 were caused by the patient's own colonising strains acquired prior to admission. In Australia, CA-MRSA clones such as PVL-positive ST93-IV [2B] (Queensland CA-MRSA) and PVL-negative ST1-IV [2B] are well established in the community and therefore it is important to monitor antimicrobial-resistance patterns in both community and healthcare associated SAB as this information will guide therapeutic practices in treating *S. aureus* sepsis.

In conclusion, ASSOP 2016 has demonstrated antimicrobial-resistance in SAB in Australia continues to be a significant problem and continues to be associated with a high mortality. This may be due, in part, to the high prevalence of methicillin-resistant SAB in Australia, which is significantly higher than most EU/EEA countries. Consequently MRSA must remain a public

health priority and continuous surveillance of SAB and its outcomes and the implementation of comprehensive MRSA strategies targeting hospitals and long-term care facilities are essential.

## Acknowledgments

This study was funded by a grant from the Australian Commission on Safety and Quality in Healthcare.

Members of the AGAR in 2016 were:

### Australian Capital Territory

Peter Collignon and Susan Bradbury, The Canberra Hospital

### New South Wales

Thomas Gottlieb and Graham Robertson, Concord Hospital

James Branley and Donna Barbaro, Nepean Hospital

Peter Huntington, Royal North Shore Hospital

Sebastian van Hal and Alicia Beukers, Royal Prince Alfred Hospital

Jon Iredell and Andrew Ginn, Westmead Hospital

Rod Givney and Ian Winney, John Hunter Hospital

Peter Newton and Melissa Hoddle, Wollongong Hospital

### Northern Territory

Rob Baird and Jann Hennessy, Royal Darwin Hospital

James McLeod, Alice Springs Hospital

## Queensland

Enzo Binotto and Bronwyn Thomsett,  
Pathology Queensland Cairns Base Hospital

Graeme Nimmo and Narelle George, Pathology  
Queensland Central Laboratory, Royal Brisbane  
and Women's Hospital

Sam Maloney and Cheryl Curtis, Pathology  
Queensland Gold Coast Hospital

Robert Horvath and Laura Martin, Pathology  
Queensland Prince Charles Hospital

Naomi Runnegar and Joel Douglas, Pathology  
Queensland Princess Alexandra Hospital

Jenny Robson and Georgia Peachey, Sullivan  
Nicolaides Pathology, Greenslopes Hospital

## South Australia

Kelly Papanoum and Nicholas Wells, SA  
Pathology (Flinders Medical Centre)

Morgyn Warner and Kija Smith, SA Pathology  
(Royal Adelaide Hospital and Women's and  
Children's Hospital)

## Tasmania

Louise Cooley and David Jones,  
Royal Hobart Hospital

Pankaja Kalukottege and Kathy Wilcox,  
Launceston General Hospital

## Victoria

Denis Spelman and Rose Bernhard,  
The Alfred Hospital

Paul Johnson and Frances Hurren,  
Austin Hospital

Tony Korman and Despina Kotsanas,  
Monash Medical Centre

Andrew Daley and Gena Gonis,  
Royal Women's Hospital

Mary Jo Waters and Lisa Brenton,  
St Vincent's Hospital

## Western Australia

David McGeachie and Denise Daley,  
PathWest Laboratory Medicine –  
WA Fiona Stanley Hospital

Ronan Murray and Jacinta Bowman,  
PathWest Laboratory Medicine –  
WA Sir Charles Gairdner Hospital

Michael Leung and Jacinta Bowman, PathWest  
Laboratory Medicine – Northwest WA

Owen Robinson and Geoffrey Coombs,  
PathWest Laboratory Medicine –  
WA Royal Perth Hospital

Sudha Pottumarthy-Boddu and Fay Kappler,  
Australian Clinical Laboratories, St John of  
God Hospital, Murdoch

Shalinie Perera and Ian Meyer, Western  
Diagnostic Pathology, Joondalup Hospital

## Author Details

Prof Geoffrey W Coombs<sup>1,2</sup>, Ms Denise  
A Daley<sup>3</sup>, Ms Yung Thin Lee<sup>1</sup>, Dr Stanley  
Pang<sup>1,2</sup> on behalf of the Australian Group on  
Antimicrobial-resistance

1. Antimicrobial-resistance and Infectious Diseases (AMRID) Research Laboratory, School of Veterinary and Life Sciences, Murdoch University, Murdoch, Western Australia, Australia
2. Department of Microbiology, PathWest Laboratory Medicine-WA, Fiona Stanley Hospital, Murdoch, Western Australia, Australia
3. Australian Group on Antimicrobial-resistance, Fiona Stanley Hospital, Murdoch,

Western Australia, Australia

## Corresponding Author

Prof Geoffrey Coombs

Antimicrobial-resistance and Infectious Diseases (AMRID) Research Laboratory, School of Veterinary and Life Sciences, Murdoch University, Murdoch, Western Australia, Australia

Telephone: +61 8 6152 2397

Email: g.coombs@murdoch.edu.au

## References

1. Laupland KB. Incidence of bloodstream infection: a review of population-based studies. *Clin Microbiol Infect* 2013; 19: 492-500.
2. Johnson AP, Pearson A, Duckworth G. Surveillance and epidemiology of MRSA bacteraemia in the UK. *J Antimicrob Chemother* 2005; 56: 455-62.
3. Thwaites GE, Edgeworth JD, Gkrania-Klotsas E et al. Clinical management of Staphylococcus aureus bacteraemia. *Lancet Infect Dis* 2011; 11: 208-22.
4. Collignon P, Nimmo GR, Gottlieb T et al. Staphylococcus aureus bacteremia, Australia. *Emerg Infect Dis* 2005; 11: 554-61.
5. Frederiksen MS, Espersen F, Frimodt-Moller N et al. Changing epidemiology of pediatric Staphylococcus aureus bacteremia in Denmark from 1971 through 2000. *Pediatr Infect Dis J* 2007; 26: 398-405.
6. Benfield T, Espersen F, Frimodt-Moller N et al. Increasing incidence but decreasing in-hospital mortality of adult Staphylococcus aureus bacteraemia between 1981 and 2000. *Clin Microbiol Infect* 2007; 13: 257-63.
7. van Hal SJ, Jensen SO, Vaska VL et al. Predictors of mortality in Staphylococcus aureus Bacteremia. *Clin Microbiol Rev* 2012; 25: 362-86.
8. Kaasch AJ, Barlow G, Edgeworth JD et al. Staphylococcus aureus bloodstream infection: a pooled analysis of five prospective, observational studies. *J Infect* 2014; 68: 242-51.
9. Turnidge JD, Kotsanas D, Munckhof W et al. Staphylococcus aureus bacteraemia: a major cause of mortality in Australia and New Zealand. *Med J Aust* 2009; 191: 368-73.
10. Nimmo GR, Bell JM, Collignon PJ. Fifteen years of surveillance by the Australian Group for Antimicrobial-resistance (AGAR). *Commun Dis Intell* 2003; 27 Suppl: S47-54.
11. Coombs GW, Nimmo GR, Daly DA et al. Australian Staphylococcus aureus Sepsis Outcome Programme annual report, 2013. *Commun Dis Intell* 2014; 38: E309-19.
12. CLSI. Performance standards for antimicrobial susceptibility testing. *Twenty-fourth informational supplement M100-S24*. Villanova, PA, USA, 2014.
13. European Committee on Antimicrobial Susceptibility Testing. Clinical breakpoints. 2014.
14. Seemann T, Goncalves da Silva A, Bulach DM, Schultz MB, Kwong JC, Howden BP. Nullarbor. San Francisco; Github. [Accessed: 03 Jun 2016]. Available from: <https://github.com/tseemann/nullarbor>
15. Bartels MD, Petersen A, Worning P, Nielsen JB, Lerner-Svensson H, Johansen HK, Andersen LP, Jarlov JO, Boye K, Larsen AR, Westh H. Comparing whole-genome sequencing with Sanger sequencing for spa typing of methicillin-resistant Staphylococcus aureus. *J. Clin. Microbiol.* 2014. 52(12): 4305-8.
16. Monecke, S., Slickers, P. and Ehrlich, R. (2008), Assignment of *Staphylococcus aureus*

- isolates to clonal complexes based on microarray analysis and pattern recognition. *FEMS Immunology & Medical Microbiology*, 53: 237–251.
17. Australian Group on Antimicrobial-resistance Australian Staphylococcus aureus Sepsis Outcome Programme annual report, 2014. Coombs GW, Daley DA, Thin Lee Y, Pearson JC, Robinson JO, Nimmo GR, Collignon P, Howden BP, Bell JM, Turnidge JD; Australian Group on Antimicrobial-resistance. *Commun Dis Intell Q Rep*. 2016 Jun 30;40(2):E244-54. PMID: 27522136 Free Article
  18. Turnidge JD, Nimmo GR, Pearson J et al. Epidemiology and outcomes for Staphylococcus aureus bacteraemia in Australian hospitals, 2005-06: report from the Australian Group on Antimicrobial-resistance. *Commun Dis Intell* 2007; 31: 398-403.
  19. Johnson AP, Davies J, Guy R et al. Mandatory surveillance of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in England: the first 10 years. *J Antimicrob Chemother* 2012; 67: 802-9.
  20. de Kraker ME, Davey PG, Grundmann H et al. Mortality and hospital stay associated with resistant Staphylococcus aureus and Escherichia coli bacteremia: estimating the burden of antibiotic resistance in Europe. *PLoS Med* 2011; 8: e1001104.
  21. Johnson PD, Martin R, Burrell LJ et al. Efficacy of an alcohol/chlorhexidine hand hygiene program in a hospital with high rates of nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection. *Med J Aust* 2005; 183: 509-14.
  22. Vos MC, Behrendt MD, Melles DC et al. 5 years of experience implementing a methicillin-resistant Staphylococcus aureus search and destroy policy at the largest university medical center in the Netherlands. *Infect Control Hosp Epidemiol* 2009; 30: 977-84.
  23. Grayson ML, Jarvie LJ, Martin R et al. Significant reductions in methicillin-resistant Staphylococcus aureus bacteraemia and clinical isolates associated with a multisite, hand hygiene culture-change program and subsequent successful statewide roll-out. *Med J Aust* 2008; 188: 633-40.
  24. Kim YC, Kim MH, Song JE et al. Trend of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in an institution with a high rate of MRSA after the reinforcement of antibiotic stewardship and hand hygiene. *Am J Infect Control* 2013; 41: e39-43.
  25. Lawes T, Edwards B, Lopez-Lozano JM et al. Trends in Staphylococcus aureus bacteraemia and impacts of infection control practices including universal MRSA admission screening in a hospital in Scotland, 2006-2010: retrospective cohort study and time-series intervention analysis. *BMJ Open* 2012; 2.
  26. Chua KY, Monk IR, Lin YH et al. Hyper-expression of alpha-hemolysin explains enhanced virulence of sequence type 93 community-associated methicillin-resistant Staphylococcus aureus. *BMC Microbiol* 2014; 14: 31.
  27. Coombs GW PJ, Nimmo GR, Collignon PJ, Bell JM, McLaws M-L, Christiansen KJ, Turnidge JD, on behalf of the Australian Group on Antimicrobial-resistance. Antimicrobial susceptibility of Staphylococcus aureus and molecular epidemiology of methicillin-resistant S. aureus isolated from Australian hospital inpatients: Report from the Australian Group on Antimicrobial-resistance 2011 Staphylococcus aureus Surveillance Programme. *J Glob Antimicrob Resis* 2013; 1: 149-56.
  28. Nimmo GR. USA300 abroad: global spread of a virulent strain of community-associated methicillin-resistant Staphylococcus aureus. *Clin Microbiol Infect* 2012; 18: 725-34.
  29. O'Brien FG, Pearman JW, Gracey M et al.

Community strain of methicillin-resistant *Staphylococcus aureus* involved in a hospital outbreak. *J Clin Microbiol* 1999; 37: 2858-62.

30. Schlebusch S, Price GR, Hinds S et al. First outbreak of PVL-positive nonmultiresistant MRSA in a neonatal ICU in Australia: comparison of MALDI-TOF and SNP-plus-binary gene typing. *Eur J Clin Microbiol Infect Dis* 2010; 29: 1311-4.
31. Coombs GW, Daley DA, Lee YT, Pang S, Bell JM, Turnidge JD for the Australian Group on Antimicrobial-resistance. Australian Group on Antimicrobial-resistance (AGAR) Australian *Staphylococcus aureus* Sepsis Outcome Programme (ASSOP) Annual Report 2015 - submitted for publication. *Commun Dis Intell*